Financial impact of sarcopenia or low muscle mass – A short review

Norman, Kristina; Otten, L.

doi:10.1016/j.clnu.2018.09.026

Cited by 84 publications

(54 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia results in a higher risk of disability, depression, mortality, increasing the risk of fall-related injury and the possibility of being admitted to a long-term care facility [10][11][12][13]. The health care cost of sarcopenia in the United States alone was estimated at $18.5 billion or approximately 1.5% of total healthcare expenditure in the year 2000 [14,15]. Additionally, sarcopenia will increase hospitalization costs by 34% among patients 65 years and older [16].…”

Section: Introductionmentioning

confidence: 99%

Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis

Ning

Xiao

et al. 2020

Eur Rev Aging Phys Act

View full text Add to dashboard Cite

Background Sarcopenia, a progressive loss of muscle mass and function with advancing age, is a prevalent condition among older adults. As most older people are too frail to do intensive exercise and vibration therapy has low risk and ease of participation, it may be more readily accepted by elderly individuals. However, it remains unclear whether vibration therapy would be effective among older adults with sarcopenia. This systematic review and meta-analysis examined the effect of vibration therapy including local vibration therapy and whole-body vibration therapy, for enhancing muscle mass, muscle strength and physical function in older people with sarcopenia. Methods A systematic literature search was conducted in March 2019 in the following 5 electronic databases: PubMed, CINAHL, Embase, PEDro, and the Cochrane Central Register of Controlled Trials, with no restriction of language or the year of publication. Randomized controlled trials and quasi-experimental studies examining effects of vibration therapy on muscle mass, muscle strength or physical function in older adults with sarcopenia were included in this systematic review. Two reviewers independently assessed the methodological quality of the selected studies. Results Of the 1972 identified studies, seven publications from six studies involving 223 participants were included in this systematic review. Five of them conducted whole-body vibration therapy, while two conducted local vibration therapy. A meta-analysis of randomized controlled studies indicated that muscle strength significantly increased after whole-body vibration therapy (SMD 0.69, 95% CI 0.28 to 1.11, I2 = 0%, P = 0.001) and local vibration therapy (SMD 3.78, 95% CI 2.29 to 5.28, P < 0.001). Physical performance measured by the sit-to-stand test and the timed-up-and-go test were significantly improved after the intervention (SMD -0.79, 95% CI − 1.21 to − 0.37, I2 = 0%, P < 0.001) and SMD -0.83, 95% CI − 1.56 to − 0.11, I2 = 64%, P = 0.02, respectively). Conclusion Vibration therapy could be a prospective strategy for improving muscle strength and physical performance in older adults with sarcopenia. However, due to the limited number of the included studies, caution is needed when interpreting these results. More well-designed, large sample size studies should be conducted to further explore and validate the benefits of vibration therapy for this population.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis

Ning

Xiao

et al. 2020

Eur Rev Aging Phys Act

View full text Add to dashboard Cite

show abstract

“…On the other hand, sarcopenia is a disease entity combining poor muscle function and diminished skeletal muscle mass (SMM), which results in frailty, cachexia, and osteoporosis [21,22,23,24,25,26,27,28,29,30,31,32]. It can also be associated with worse patient QOL, prognosis and higher health care costs in various diseases including CLDs [22,24,26].…”

Section: Introductionmentioning

confidence: 99%

Effect of Sarcopenia on Sleep Disturbance in Patients with Chronic Liver Diseases

Nishikawa

Enomoto

Iwata

et al. 2018

JCM

View full text Add to dashboard Cite

We sought to investigate the influence of sarcopenia as defined by muscle strength and skeletal muscle mass (SMM) on sleep disturbance as evaluated by the Japanese version of Pittsburgh Sleep Quality Index (PSQI-J) in chronic liver diseases (CLDs) (n = 419). Muscle strength and muscle mass were determined by grip strength (GS) and SMM using bioimpedance analysis. Patients were classified into four types: type A (n = 61); decreased GS and decreased SMM; type B (n = 45); decreased GS and non-decreased SMM; type C (n = 102); non-decreased GS and decreased SMM; and type D (n = 211); non-decreased GS and non-decreased SMM. Factors associated with PSQI-J score 6 or more were examined. PSQI-J score 0–5 (normal) was found in 253 (60.4%); 6–8 (mild) in 97 (23.2%); 9–11 (moderate) in 45 (10.7%) and 12 or more (severe) in 24 (5.7%). Univariate analysis identified three factors to be significantly associated with PSQI-J score 6 or more: presence of liver cirrhosis (LC) (P = 0.0132); our classification of type A; B; C and D (P < 0.0001) and serum albumin level (P = 0.0041). Multivariate analysis showed that type A (P = 0.0021) and type B (P = 0.0220) were significant independent factors. In conclusion, sarcopenia in CLDs appears to be closely associated with sleep disturbance mainly due to muscle strength decline.

show abstract

“…Muscle is also critical component of diseases such as chronic obstructive pulmonary disorder, diabetes, cancer, anemia, and sepsis [4][5][6] . The clinical and financial burden of loss of muscle mass to society is enormous 7 , and it is therefore vital to develop strategies to prevent loss of muscle mass, or to maintain and even increase muscle mass. To do so, we need to improve our understanding of the underlying molecular mechanisms that control skeletal muscle mass.…”

mentioning

confidence: 99%

PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase

et al. 2020

View full text Add to dashboard Cite

mTORC1 is an important regulator of muscle mass but how it is modulated by oxygen and nutrients is not completely understood. We show that loss of the prolyl hydroxylase domain isoform 1 oxygen sensor in mice (PHD1 KO) reduces muscle mass. PHD1 KO muscles show impaired mTORC1 activation in response to leucine whereas mTORC1 activation by growth factors or eccentric contractions was preserved. The ability of PHD1 to promote mTORC1 activity is independent of its hydroxylation activity but is caused by decreased protein content of the leucyl tRNA synthetase (LRS) leucine sensor. Mechanistically, PHD1 interacts with and stabilizes LRS. This interaction is promoted during oxygen and amino acid depletion and protects LRS from degradation. Finally, elderly subjects have lower PHD1 levels and LRS activity in muscle from aged versus young human subjects. In conclusion, PHD1 ensures an optimal mTORC1 response to leucine after episodes of metabolic scarcity.

show abstract

Financial impact of sarcopenia or low muscle mass – A short review

Cited by 84 publications

References 28 publications

Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis

Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis

Effect of Sarcopenia on Sleep Disturbance in Patients with Chronic Liver Diseases

PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase

Contact Info

Product

Resources

About